Compare Gilead Sciences, Inc. (GILD) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Okta, Inc. — how do they compare? Gilead Sciences, Inc. trades at $134.45 (market cap $163.51B), while Okta, Inc. trades at $149.46 (market cap $26.22B). The key difference: Gilead Sciences, Inc. is far larger — about 6.2× Okta, Inc.'s market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Okta, Inc. pays none. Which is the better fit depends on your goals.
| GILD | OKTA | |
|---|---|---|
Market Cap | $163.51B | $26.22B |
Sector | Health | Technology |
52-Week High | $155.80 | $154.62 |
52-Week Low | $108.22 | $62.93 |
Enterprise Value | $178.05B | $24.04B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
OKTA trades at $150.97, down 2.36% on the day, with a bullish technical outlook supported by moving averages and strong institutional interest. The company reported revenue of $2.61B in 2025, achieving positive net income of $28M after years of losses, and has beaten earnings estimates for three consecutive quarters. Analyst consensus is strongly bullish with 72.55% buy ratings, though the stock trades above the consensus price target of $125.78.
The outlook for OKTA is positive due to robust revenue growth, improving profitability, and strong demand for AI-driven cybersecurity solutions. Key risks include high valuation multiples, intense competition, and sensitivity to enterprise IT spending cycles. The stock presents a growth opportunity but requires monitoring of execution and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
